Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05580016
Other study ID # GRADIENT
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 9, 2023
Est. completion date December 27, 2023

Study information

Verified date January 2024
Source Poitiers University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Soluble Urokinase Plasminogen Activation Receptor (SUPAR) is a validated biomarker with applications in the study of inflammation and infection. Elevated levels of SUPAR have recently been linked to a higher mortality in patients suffering from undifferentiated sepsis, pneumonia, and more recently, COVID-19 infection. Large randomized controlled trials have been conducted on patients admitted to the emergency department (ER), regardless of the reason for admittance. These studies have stratified risk based on three cutoffs at initial measurement: - Low risk : < 3 ng/mL - Intermediate risk : entre 3 et 6 ng/mL - High risk : > 6 ng/mL Low levels of SUPAR are associated with low risk of mortality in the short and long term in patients presenting to the ED, no matter the reason for admittance. Risk stratification could be an added decision-making tool for clinicians to comfort hospital discharge. To the best of our knowledge, there is no available data on the added value of SUPAR for predicting mortality in abdominal sepsis and abdominal pain. Abdominal pain is responsible for 10 to 30 % of ER admissions. Consequently, abdominal pain is then responsible for roughly 10 % of admissions into medical and surgical wards. Mortality varies depending on patient factors. Mortality is usually stratified on age. In patients under 50 years of age, it is near 8%, but it reaches 19 % in patients over 50. Diagnostic accuracy also decreases drastically with age, reaching approximately 30 % patients over 75. Taking this into account, integrating a measure of SUPAR levels into the current standard of care could stratify the risk of complications in patients admitted to the ER with abdominal pain.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date December 27, 2023
Est. primary completion date November 27, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients : - Over 18 years of age - Presenting to the ED with abdominal pain for over an hour - Classified as category 2 or above on the CIMU or FRENCH severity scale - Necessitating bloodwork at the discretion of the consulting physician - Who gave his Non-opposition after clear and fair information on the study Exclusion Criteria: Patients : - With pain evocative of kidney stones - With a chronic inflammatory disease: HIV infection, inflammatory bowel disease, rheumatoid arthritis, cancer - Chronic renal disease - Under hospice care - Intubated - Unstable hemodynamically - Transferred from a secondary care facility and having undergone previous bloodwork - Patient unable to understand the information and to give his non-objection - under guardianship, curatorship or subordination; - benefiting from enhanced protection, namely: minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in an establishment health or social, adults under legal protection

Study Design


Intervention

Diagnostic Test:
Soluble Urokinase Plasminogen Activation Receptor measurement
In addition to the standard of care, Soluble Urokinase Plasminogen Activation Receptor levels will be measured in patients.

Locations

Country Name City State
France CHU of Poitiers Poitiers

Sponsors (1)

Lead Sponsor Collaborator
Poitiers University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of medical and surgical complications within 7 days 7 -day complications as a composite outcome of either:
Necessity of surgical intervention
Hospitalisation lasting over 24 hours
Death in direct relation to the reason for admittance
Hospital readmission for abdominal pain in a similar abdominal quadrant
7 days
Secondary Occurrence of medical and surgical complications within 30 days 30 -day complications as a composite outcome of either:
Necessity of surgical intervention
Hospitalisation lasting over 24 hours
Death in direct relation to the reason for admittance
Hospital readmission for abdominal pain in a similar abdominal quadrant
30 days
Secondary Optimal cutoff Determining optimal cutoffs for Soluble Urokinase Plasminogen Activation Receptor through Area Under Curve using Receiver Operating Characteristic method for patients presenting complications of abdominal pain in the first seven days. 7 days
Secondary Comparison with routine biomarkers Comparison of diagnostic performance with other routine biomarkers:
Procalcitonine C-Reactive Protein Lactate
30 days
See also
  Status Clinical Trial Phase
Completed NCT04682860 - Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide Phase 4
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT02923245 - POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02547857 - Transvaginal Pelvic Ultrasound in the ED N/A
Completed NCT02676232 - DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families. N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Recruiting NCT00209807 - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Phase 4
Terminated NCT01410071 - Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction N/A
Terminated NCT01736280 - Evaluating and Treating Potential Research Participants With Digestive Disorders N/A
Enrolling by invitation NCT04104867 - Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy N/A
Completed NCT03574727 - Abdominal Cutaneous Nerve Entrapment Syndrome
Completed NCT04614649 - Right Iliac Fossa Treatment-Turkey Audit
Completed NCT05438654 - Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain N/A
Completed NCT06423586 - Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS N/A
Completed NCT03558009 - Epidemiological Analysis for Hereditary Angioedema Disease
Terminated NCT03148288 - Vitamin D Supplementation in IBS N/A
Completed NCT03708874 - Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
Withdrawn NCT04408872 - EUS vs EGD in Emergency Room Patients Referred for EGD N/A
Recruiting NCT02594774 - Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents N/A